Iani Patsias, MD
Cardiovascular Disease · Hollywood, FLNPI 1710253331
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Abbott at 48.1% of the total. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 14 payments — averaging $119.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$802
- Prolaio, Inc.$800
- Philips North America LLC$38
- Bayer$18
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8
Across 10 payments — averaging $2366.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Prolaio, Inc.$17K
- Abbott$6K
What the payments were for
- Consulting fees$80048%
- Travel & lodging$342%
- Food & beverage$61937%
- Education$21313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 10 | $802 |
| Prolaio, Inc. | 1 | $800 |
| Philips North America LLC | 1 | $38 |
| Bayer | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,666 in reported general payments places this provider in the 35th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 95 | $2,100,149 |
| UptraviSelexipag | 44 | $1,135,120 |
| OpsumitMacitentan | 39 | $508,687 |
| EntrestoSacubitril/Valsartan | 257 | $278,098 |
| Tyvaso DpiTreprostinil | 12 | $270,540 |
| FarxigaDapagliflozin Propanediol | 255 | $245,218 |
| VyndaqelTafamidis Meglumine | 11 | $231,531 |
| CamzyosMavacamten | 27 | $217,903 |
| Orenitram ErTreprostinil Diolamine | 30 | $162,827 |
| JardianceEmpagliflozin | 109 | $100,267 |
| EliquisApixaban | 108 | $89,892 |
| Ambrisentan | 12 | $34,200 |
| XareltoRivaroxaban | 41 | $27,870 |
| OzempicSemaglutide | 33 | $27,868 |
| VerquvoVericiguat | 14 | $19,052 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Hollywood
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.